A study of Thalidomide, Bendamustine, and Dexamethasone (BTD) vs Bortezomib, Bendamustine, and Dexamethasone (BBD) in patients with renal failure defined as a GFR below 30 mls/min
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 31 Oct 2017
At a glance
- Drugs Bendamustine (Primary) ; Bortezomib (Primary) ; Dexamethasone; Thalidomide
- Indications Myeloma
- Focus Therapeutic Use
- Acronyms OPTIMAL
- Sponsors Janssen-Cilag
- 31 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 12 Jun 2016 Planned End Date changed from 1 Jan 2017 to 1 Apr 2018.
- 12 Jun 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018.